p53 is a tumor suppressor with a pro-death role in many conditions. However, in some contexts, evidence supports a pro-survival function. p53 has been shown to be activated in acetaminophen (APAP) toxicity but the impact of this on toxicity is uncertain. In the present study, we have found that p53 plays a protective role in APAP-induced liver injury. We inhibited p53 using three different approaches in mice, pifithrin-α (PFTα), knockdown of p53 expression with antisense oligonucleotide, and p53 knockout. Mice were treated with APAP (300 mg/kg) i.p. and after 24 h in all three conditions, the liver injury was more severe as reflected in higher ALT levels and great area of necrosis in histology of the liver. Conversely, a p53 activator, nutlin-3a, decreased the liver injury induced by APAP. In the p53 inhibition models, enhanced sustained JNK activation was seen in the early time course, while the JNK was suppressed with the p53 activator. In conclusion, p53 plays a novel protective role in APAP induced liver injury through inhibiting the activation of JNK, a key mediator in APAPinduced oxidative stress.
Introduction
Acetaminophen (APAP)-mediated hepatotoxicity has become the leading cause of acute liver failure in United States and most of European countries since first reported in 1960s [1] . It is well established that APAP induces hepatotoxicity through mechanisms involved in production of reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI), depletion of glutathione (GSH), formation of NAPQIprotein adduct, generation of reactive oxygen species (ROS), sustained activation of JNK, disruption of mitochondrial membrane potential (MMP), and ultimately induction of necrosis of hepatocytes [2, 3] .
p53 is the first identified and the best known tumor suppressor. The role of p53 in the regulation of cell death induction is well established [4] . Activation of p53 generally serves as pro-death signal to trigger cytotoxicity. However, an increasing body of evidence supports a prosurvival function of p53 activation in certain conditions [5] [6] [7] . As mentioned above, oxidative stress plays a pivotal role in hepatotoxicity of APAP. Induction of oxidative stress can trigger p53 activation. Indeed, previous studies have shown that p53 is activated in response to APAP exposure in both cell culture and animal models [8] . However,
Animal experiments
Male C57BL/6N wildtype mice (19-20 g ) were purchased from Harlan Bioproducts for Science Inc. (Indianapolis, IN, USA). These mice were administrated by antisense oligonucleotide. These experiments were performed at the Kaplowitz lab, University of Southern California. The remainder of in vivo studies were performed in China Agricultural University, Beijing. Male C57BL/6N or J substrain p53 knockout and paired wildtype mice (19-20 g) were purchased from Beijing Vitalstar Biotechnology Co. Ltd (Beijing, China). All mice were housed in a temperature-, light-, and humidity-controlled environment that is accredited by the Associated for Assessment and Accreditation of Laboratory Animal Care. Mice were maintained on standard laboratory chow and had free access to water. All mice were overnight fasted. PFTα (2.2 mg/kg, i.p.), dissolved in PBS: DMSO (9:1) and nutilin-3a, (10 mg/kg, by gavage), dissolved in 2% Klucel, 0.5% Tween 80, were pretreated 1 h before APAP administration. Controls received vehicles. APAP was dissolved in warm PBS and given at 300 mg/kg, i.p. Serum and liver tissue were collected 1 h, 2 h, 4 h and 24 h after APAP (300 mg/kg, i.p).
Antisense oligonucleotide treatment of mice
Antisense oligonucleotide (ASO) was provided by Ionis Phamarceuticals, Carlsbad, CA. Control ASO (CCTTCCCTGAAGGTT-CCTCC) and p53 ASO (GTGACTCCTCCATGGCAGTC) Oligonucleotides were synthesized as 20-nt uniform phosphorothioate chimeric oligonucleotides and purified. Oligonucleotides were chimeric containing five nuclease resistant 2-O-methoxyethylribose-modified phosphorothioate residues on the 5́and 3-ends, flanking a 2-deoxyribonucleotide/ phosphorothioate region that supports RNase H-based cleavage of the targeted mRNA. 50 mg/kg control ASO and p53 ASO were i.p. injected every other day for 2 weeks.
Genotyping
The protocol for this study was approved by the Animal Care and Utilization Committee of China Agricultural University. Genotypes of the p53-deficient mice were examined by Polymerase chain reaction (PCR). Three primers for detection are listed as follows. Wild type primer (named p53-4) is CTgATCgTTACTCggCTTgTCC, Common primer (named p53-6) is CTgTCTTCCAgATACTCgggATAC, and mutant primer (named TWB-12) is ATCgCCTTCATACgCCTTCTTgACgAgTTC. PCR were carried out for 1 cycles (98°C, 1 min; 68°C, 1 min, 20 s) and 32 cycles (94°C, 30 s; 60°C, 30 s; and 72°C, 1 min). The expected results were as follows: mutant=286 bp (primers of p53-6 & TWB-12); wild type=381 bp (primers of p53-4 & p53-6); heterozygote=286 bp and 381 bp.
Western blotting
The cell lysate and tissues were prepared in ice-cold radioimmunoprecipitation (RIPA) assay buffer. SDS-PAGE electrophoresis was performed and then protein was transfer to 0.2 µm nitrocellulose (NC) membrane (Millipore, Bedford, MA, USA). After blocking in 5% milk, the blots were probed with primary antibody followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies. The signal was visualized by enhanced chemiluminescence (Fisher/Pierce, Rockford. IL, USA) and recorded on an X-ray film (Estman Kodak Company, Rochester, NY, USA).
Primary mouse hepatocyte culture
Primary mouse hepatocytes were isolated from control ASO and p53 ASO treated mice as described [9] . The viability of cells exceeded 88%. After plating, the medium was replaced with DMEM/F12 containing 10 mM APAP. Whole cell lysate was collected after 1 h, 2 h and 4 h of exposure to APAP.
Histology
After fixed in formalin for 24 h, the tissue was paraffin-embedded. And then the tissue paraffin embedded blocks was cut for 5 µm thick. The liver sections were stained with hematoxylin and eosin (H & E).
GSH Measurement
Liver GSH was measured using colorimetric kits (#A006-2, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The tissue was homogenized in metaphosphoric acid, and centrifuged at 3000g at 4 ℃ for 10 min. The upper aqueous layer was collected for measurement and mixed with 20 μL sample and 120 μL DTNB: Glutathione Reductase=1:1 solution; after 30 s, 60 μL B-NADPH was added and the absorbance at 412 nm was immediately read in microplate reader. The rate of 2-nitro-5-thiobenzoic acid formation was then calculated from a standard curve.
ALT measurements
Serum ALT was measured using colorimetric kits (#C009-2, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Serum (5 μL) and ALT substrate (25 μL) were added to each well and placed in a 37°C heating bath. After exactly 30 min, 25 μL of ALT Color Reagent was added to each well, maintaining the timed interval sequence. After an additional 10 min incubation at 37°C, 200 μL of ALT Color Developer was added (maintaining the same timed intervals). After 15 min at room temperature, absorbance of all wells was measured at 510 nm. 
Statistical analysis
Data are presented as the mean ± SD. T-test was used for comparison of two groups. P < 0.05 was considered statistically significant.
Results

p53 inhibition by pharmacological approach triggered more severe liver injury in APAP model
It was previously reported that p53 is activated after APAP administration as reflected in activation of p53 response genes at 6 h after APAP, but no clear evidence exists as to whether p53 plays a damaging or protective role. [8] . PFTα, a small molecule p53 inhibitor, effectively blocks p53-dependent transcriptional activation [10] . We pretreated mice with PFTα (2.2 mg/kg, i.p) 1 h before APAP administration and serum and liver were collected after 24 h. Bax, a downstream target of p53, was decreased by PFTα pretreatment providing evidence of successful inhibition of p53 (Fig. 1A) . Nevertheless, APAPinduced elevation in serum ALT (Fig. 1B ) was higher and hepatic necrosis were more severe (Fig. 1C) in PFTα plus APAP group than APAP alone group. 
p53 knockdown or knockout enhanced APAP-induced liver injury
p53 was successfully knocked-down by ASO pretreatment 7 times every other day in vivo (58% decrease) ( Fig. 2A) . APAP was administrated on the second day after completing treatment. Serum and liver tissue was collected 24 h later. As shown in Fig. 2B & C, knockdown of p53 lead to increased injury as reflected in serum ALT and histology.
To further explore the role of p53 in APAP-induced liver injury, p53-/-mice and strain matched WT mice were treated with 300 mg/kg APAP i.p. As shown in Fig. 3A , genotyping p53 KO mice confirmed homozygous deletion of p53. Notably, the amplitude of elevation of ALT in p53 KO mice was markedly higher than WT mice (Fig. 3B) . Consistent with serological analysis, H & E histological analysis also showed more severe liver injury in p53 deficiency (Fig. 3C) .
Taken together, p53 deficiency either by chemical inhibitor, ASO knockdown or gene knockout rendered mice more susceptible to APAP hepatotoxicity, suggesting that p53 plays a protective role in dampening the hepatotoxicity induced by APAP.
The suppression of p53 did not affect the metabolism of APAP
To decipher the molecular basis of the role of p53 in APAP model, we measured the levels of the important APAP metabolism enzyme cyp2e1 in both p53 KO and PFTα-pretreated mice. As shown in Fig. 4A & B, there was no difference with p53 deficiency. In addition, GSH was almost completely depleted at 2 h after APAP in both WT and p53 KO mice. p53 deficiency had no influence on the decline of GSH or its recovery (Fig. 4C ) and the generation of NAPQI adducts (Fig. 4D) . This result suggested that the protective role of p53 was not due to a change of APAP toxic metabolite production.
The suppression of p53 increased the activation of p-JNK
It is well established that APAP induces mitochondrial superoxide which then leads to sustained JNK activation (p-JNK) in the early time course prior to necrosis. APAP administration alone caused upregulation of p-JNK level as expected, while PFTα-pretreated and p53 knockout mice showed markedly enhanced expression of p-JNK (Fig. 5A & B) . In order to confirm the specific function of p53 in hepatocytes, we isolated primary mouse hepatocytes after p53 ASO treatment. The p-JNK level in p53 deficient hepatocytes isolated from p53 ASO treated mice was significantly enhanced by 10 mM APAP treatment at 4 h compared to control ASO hepatocytes (Fig. 5C ). These data suggest that endogenous p53 was associated with dampening of sustained p-JNK.
Activation of p53 attenuated the liver injury in APAP model
To ascertain whether pharmacological stimulation of p53 could attenuate the liver injury induced by APAP, we pretreated the mice with 10 mg/kg nutlin-3a by gavage (1 h before APAP i.p injection) [11] . Nutlin 3a is a small-molecule antagonist of MDM2 which stabilizes p53 [12] . As shown in Fig. 6A, p53 was increased in nutlin3a-treated mice compared to vehicle group. Nutlin-3a pretreatment decreased APAP-induced elevation of ALT at 24 h (Fig. 6B ). In line with ALT results, histological analysis also revealed that nutlin-3a alleviated the centrilobular necrosis of the liver after APAP administration (Fig. 6C) . These results showed that pharmacological induction of p53 may be beneficial for APAP-induced liver injury. p53 activation had no influence on the decline of GSH (Fig. 6D) . To confirm the regulation of p-JNK by p53, we measured the expression of p-JNK after nutlin-3a. p-JNK protein level was downregulated at 6 h after APAP (Fig. 6E) , suggesting that the protective role of p53 was due to the decrease sustained phosphorylation of JNK induced by APAP.
Discussion
Activation of p53 can function in either pro-death or pro-survival signaling in response to oxidative stress. Oxidative stress has been shown to play a critical role in APAP-induced hepatotoxicity [13] . The objective of the present studies was designed to address the functional role of p53 in APAP-induced acute liver injury. The results of the present study showed that inactivation of p53 by either genetic approach or a chemical inhibitor led to a significant enhanced APAPinduced hepatotoxicity, whereas activation of p53 by its activator resulted in an attenuated liver injury by APAP, indicating a pro-survival function of p53 in response to APAP exposure. The findings of the present study suggest that manipulation of p53 may be a useful approach to protect against APAP-induced acute liver injury.
Regarding the mechanisms underlying the protective role of p53 in APAP-induced liver injury, we first investigated influence of p53 inactivation on APAP-induced cyp2e1 and GSH depletion, and the results indicated that inhibition of p53 affected neither of these parameters, suggesting the toxic metabolism stage of APAP is not the target for p53 to exert its protective activity. We next assessed the effect of p53 inactivation on the changes of APAP-induced sustained JNK activation, a key event downstream of APAP metabolism but upstream of APAP-induced necrosis. The data revealed that JNK phosphorylation was enhanced when p53 was inactivated by either knockout or knockdown or pharmacological approach. Conversely, JNK phosphorylation was decreased when p53 was activated by nutlin-3a, an inhibitor of MDM2 which then inhibits p53 degradation. Together, these results suggest that p53 can counteract APAP-mediated toxic JNK activation. The findings provide a mechanistic support for the protective role of p53 in APAP-induced liver injury. p53 plays a dual role not only in the regulation of cell death, but also in the modulation of redox [14] . The pro-oxidant activity of p53 is found to contribute to its pro-death action, whereas p53's anti-oxidant activity is correlated with its pro-survival function [15] . It has been shown that JNK is initially activated by oxidative stress possibly through activating MAP3K and inhibiting MAPK phosphatases [16, 17] . Phosphorylated JNK then translocates to the mitochondria and binds to Sab, a scaffold protein, leading to disruption of mitochondrial electron transport chain and the production of ROS, which causes continuously activated MAPK cascade through a self-sustaining MLK3/ ASK1→p-MKK4→p-JNK→Sab→ROS pathway [18, 19] . Based on the relationship between ROS generation and JNK activation in response to APAP exposure, we speculate that p53 activation by APAP exerts antioxidant activity possibly through up-regulation of a number of antioxidant enzymes to inhibit ROS-JNK-ROS loop. An alternative hypothesis is that p53 directly inhibits p-JNK. p53 has been shown to bind to p-JNK and inhibits its activity which would therefore potentially interrupt the p-JNK→Sab→ROS→→p-JNK loop sustaining pathway. These hypotheses need to be tested in future studies.
In summary, p53 was activated in response to APAP-mediated oxidative stress and p53 protected against APAP-induced hepatotoxicity accompanied by suppression of sustained JNK activation, leading to the hypothesis that p53 interference with the JNK activation pathway accounts for its protective role in APAP-induced liver injury.
